eli lilly glp-1 advantage decreasing Lilly's $1 Trillion Boom: Inside Dave Ricks' Weight-Loss Bet How to Invest in GLP-1
Description
The results of cardiovascular and kidney outcomes trials involving sodiumglucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease
The company intends to broaden its applications to include not only diabetes but also obesity and NASH (non-alcoholic steatohepatitis)
Taking the tablets on an empty stomach reduces their effectiveness and may increase the likelihood of nausea, which GLP-1 users are already prone to
The association between type 2 diabetes mellitus and Parkinson's disease
An improvement in fibrosis stage was seen in 43% of the higher dose semaglutide group versus 33% of the patients in the placebo group but this was not statistically significant
